Immunogenicity of fractional doses of tetravalent a/c/y/w135 meningococcal polysaccharide vaccine: results from a randomized non-inferiority controlled trial in Uganda

Philippe J Guerin, Lisbeth M Naess, Carole Fogg, Einar Rosenqvist, Loretxu Pinoges, Francis Bajunirwe, Carolyn Nabasumba, Ray Borrow, Leif O Frøholm, Salah Ghabri, Vincent Batwala, Rogers Twesigye, Ingeborg S Aaberge, John-Arne Røttingen, Patrice Piola, Dominique A Caugant, Philippe J Guerin, Lisbeth M Naess, Carole Fogg, Einar Rosenqvist, Loretxu Pinoges, Francis Bajunirwe, Carolyn Nabasumba, Ray Borrow, Leif O Frøholm, Salah Ghabri, Vincent Batwala, Rogers Twesigye, Ingeborg S Aaberge, John-Arne Røttingen, Patrice Piola, Dominique A Caugant

Abstract

Background: Neisseria meningitidis serogroup A is the main causative pathogen of meningitis epidemics in sub-Saharan Africa. In recent years, serogroup W135 has also been the cause of epidemics. Mass vaccination campaigns with polysaccharide vaccines are key elements in controlling these epidemics. Facing global vaccine shortage, we explored the use of fractional doses of a licensed A/C/Y/W135 polysaccharide meningococcal vaccine.

Methods and findings: We conducted a randomized, non-inferiority trial in 750 healthy volunteers 2-19 years old in Mbarara, Uganda, to compare the immune response of the full dose of the vaccine versus fractional doses (1/5 or 1/10). Safety and tolerability data were collected for all subjects during the 4 weeks following the injection. Pre- and post-vaccination sera were analyzed by measuring serum bactericidal activity (SBA) with baby rabbit complement. A responder was defined as a subject with a > or =4-fold increase in SBA against a target strain from each serogroup and SBA titer > or =128. For serogroup W135, 94% and 97% of the vaccinees in the 1/5- and 1/10-dose arms, respectively, were responders, versus 94% in the full-dose arm; for serogroup A, 92% and 88% were responders, respectively, versus 95%. Non-inferiority was demonstrated between the full dose and both fractional doses in SBA seroresponse against serogroups W135 and Y, in total population analysis. Non-inferiority was shown between the full and 1/5 doses for serogroup A in the population non-immune prior to vaccination. Non-inferiority was not shown for any of the fractionate doses for serogroup C. Safety and tolerability data were favourable, as observed in other studies.

Conclusions: While the advent of conjugate A vaccine is anticipated to largely contribute to control serogroup A outbreaks in Africa, the scale-up of its production will not cover the entire "Meningitis Belt" target population for at least the next 3 to 5 years. In view of the current shortage of meningococcal vaccines for Africa, the use of 1/5 fractional doses should be considered as an alternative in mass vaccination campaigns.

Trial registration: ClinicalTrials.gov NCT00271479.

Conflict of interest statement

The authors have declared that no competing interests exist.

Figures

Figure 1. Consort flowchart.
Figure 1. Consort flowchart.
Figure 2. ELISA IgG concentrations per serogroup…
Figure 2. ELISA IgG concentrations per serogroup and per arm before the vaccination and four weeks later in the MITT population (GMC with superior limit of 95%CI).
GMC = geometric mean concentration. P<0.001 for all comparisons between the vaccination and four weeks later for all serogroups.

References

    1. Lapeyssonnie L. [Comparative epidemiologic study of meningococcic cerebrospinal meningitis in temperate regions and in the meningitis belt in Africa. Attempt at synthesis]. Med Trop. 1968;28:709–720.
    1. World Health Organization. Detecting meningococcal meningitis epidemics in highly-endemic African countries. Wkly Epidemiol Rec. 2000;75:306–309.
    1. Ouedraogo-Traore R, Hoiby EA, Sanou I, Sangare L, Kyelem N, et al. Molecular characteristics of Neisseria meningitidis strains isolated in Burkina Faso in 2001. Scand J Infect Dis. 2002;34:804–807.
    1. World Health Organization. Meningococcal disease, serogroup W135, Burkina Faso. Wkly Epidemiol Rec. 2002;77:152–155.
    1. Zombre S, Hacen MM, Ouango G, Sanou S, Adamou Y, et al. The outbreak of meningitis due to Neisseria meningitidis W135 in 2003 in Burkina Faso and the national response: main lessons learnt. Vaccine. 2007;25(Suppl 1):A69–A71.
    1. World Health Organization. Risk of epidemic meningitis in Africa: a cause for concern. Wkly Epidemiol Rec. 2007;82:79–87.
    1. Greenwood B. Editorial: 100 years of epidemic meningitis in West Africa-has anything changed? Trop Med Int Health. 2006;11:773–780.
    1. Jodar L, Feavers IM, Salisbury D, Granoff DM. Development of vaccines against meningococcal disease. Lancet. 2002;359:1499–1508.
    1. LaForce FM, Konde K, Viviani S, Preziosi MP. The Meningitis Vaccine Project. Vaccine. 2007;25(Suppl 1):A97–100.
    1. Artenstein MS, Gold R, Zimmerly JG, Wyle FA, Branche WC, Jr, et al. Cutaneous reactions and antibody response to meningococcal group C polysaccharide vaccines in man. J Infect Dis. 1970;121:372–377.
    1. Gold R, Lepow ML, Goldschneider I, Draper TL, Gotschlich EC. Clinical evaluation of group A and group C meningococcal polysaccharide vaccines in infants. J Clin Invest. 1975;56:1536–1547.
    1. Griffiss JM, Brandt BL, Broud DD. Human immune response to various doses of group Y and W135 meningococcal polysaccharide vaccines. Infect Immun. 1982;37:205–208.
    1. Griffiss JM, Brandt BL, Broud DD, Altieri PL, Berman SL. Relationship of dose to the reactogenicity and immunogenicity of meningococcal polysaccharide vaccines in adults. Mil Med. 1985;150:529–533.
    1. Brandt BL, Griffiss JM, Broud DD, Boslego JW Kluwer Academic Publishers, editors. Gonococci and Meningococci. Dordrecht, The Netherlands: 1988. Tetravalent meningococcal polysaccharide vaccine. Relashionship of dose to immunogenicity and reactogenicity in young adults. pp. 33–37.
    1. Campagne G, Schuchat A, Djibo S, Ousseini A, Cisse L, et al. Epidemiology of bacterial meningitis in Niamey, Niger, 1981–96. Bull World Health Organ. 1999;77:499–508.
    1. Lellouch J, Lazar P. Méthodes statistiques en expérimentation biologique. Paris, Flammarion. 1974
    1. Borrow R, Carlone GM. Serogroup B and C serum bactericidal assays. In: Pollard AJ MMe., editor. Meningococcal vaccines: methods and protocols. Methods in molecular medicine. Totowa (New Jersey): Humana Press; 2001. pp. 289–304.
    1. Carlone GM, Frasch CE, Siber GR, Quataert S, Gheesling LL, et al. Multicenter comparison of levels of antibody to the Neisseria meningitidis group A capsular polysaccharide measured by using an enzyme-linked immunosorbent assay. J Clin Microbiol. 1992;30:154–159.
    1. Joseph H, Balmer P, Bybel M, Papa T, Ryall R, et al. Assignment of Neisseria meningitidis serogroups A, C, W135, and Y anticapsular total immunoglobulin G (IgG), IgG1, and IgG2 concentrations to reference sera. Clin Diagn Lab Immunol. 2004;11:1–5.
    1. Caugant DA, Fogg C, Bajunirwe F, Piola P, Twesigye R, et al. Pharyngeal carriage of Neisseria meningitidis in 2-19-year-old individuals in Uganda. Trans R Soc Trop Med Hyg. 2006;100:1159–1163.
    1. Andrews N, Borrow R, Miller E. Validation of serological correlate of protection for meningococcal C conjugate vaccine by using efficacy estimates from postlicensure surveillance in England. Clin Diagn Lab Immunol. 2003;10:780–786.
    1. Goldschneider I, Gotschlich EC, Artenstein MS. Human immunity to the meningococcus. I. The role of humoral antibodies. J Exp Med. 1969;129:1307–1326.
    1. Santos GF, Deck RR, Donnelly J, Blackwelder W, Granoff DM. Importance of complement source in measuring meningococcal bactericidal titers. Clin Diagn Lab Immunol. 2001;8:616–623.
    1. Borrow R, Balmer P, Miller E. Meningococcal surrogates of protection–serum bactericidal antibody activity. Vaccine. 2005;23:2222–2227.
    1. Jodar L, Stephens D, Feavers IM. Assay parameters and methods of data analysis for the comparison of complement sources in the Neisseria meningitidis serogroup C serum bactericidal assay. Biologicals. 2002;30:323–329.
    1. Kayhty H, Karanko V, Peltola H, Sarna S, Makela PH. Serum antibodies to capsular polysaccharide vaccine of group A Neissera meningitidis followed for three years in infants and children. J Infect Dis. 1980;142:861–868.
    1. Gold R, Artenstein MS. Meningococcal infections. 2. Field trial of group C meningococcal polysaccharide vaccine in 1969-70. Bull World Health Organ. 1971;45:279–282.
    1. Yergeau A, Alain L, Pless R, Robert Y. Adverse events temporally associated with meningococcal vaccines. CMAJ. 1996;154:503–507.
    1. Patel M, Lee CK. Polysaccharide vaccines for preventing serogroup A meningococcal meningitis. Cochrane Database Syst Rev. 2005;CD001093
    1. Joint United Nations Programme on HIV/AIDS. Country situation analysis, Uganda. 2008 Available: . Accessed 11 January 2008.
    1. Meningococcal disease, Great Lakes area (Burundi, Rwanda, United Republic of Tanzania)—update. Wkly Epidemiol Rec. 2002;77:317.
    1. Obaro SK, Ota MO. Sense and the science of childhood immunization: can we achieve more with less? Vaccine. 2006;24:6460–6467.

Source: PubMed

Sponzoři a spolupracovníci

Zdravotní podmínky

Drogové intervence

3
Předplatit